June 02, 2016 | Global
Acelity Announces Intention to Amend and Extend Existing Credit Agreement

SAN ANTONIO, June 2, 2016 – Acelity L.P. Inc. (“Acelity”), a global advanced wound care and regenerative medicine company, announced today that, subject to market terms and conditions, it will seek to amend its existing credit agreement (the “Credit Agreement”) to, among other things, refinance and extend the maturity date for a portion of its existing Term E-1 Loans (the “Term E-1 Loans”) and make certain covenant modifications. The existing Term E-1 Loans are currently set to mature on May 4, 2018. 
Acelity is also currently considering alternatives to potentially refinance or extend the maturities of its outstanding second lien indebtedness. Acelity cannot provide any assurances about the timing, terms or interest rate associated with the planned refinancing and extension, or that the refinancing and extension transactions will be completed at all.

This press release does not and will not constitute an offer to sell or the solicitation of an offer to buy securities.

Forward-Looking Statements
Certain statements included in this press release may be considered “forward-looking statements”, which are based on information available to Acelity on the date of this release. Words such as “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “future,” “will,” “seek,” “foreseeable,” the negative versions of these words and or similar terms and phrases are used to identify these forward looking statements. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties. Acelity cannot assure you that future developments affecting Acelity will be those that have been anticipated. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market regulatory and other factors, many of which are beyond Acelity’s control, as well as other risks described from time to time under “Risk Factors” in Acelity’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q (available at Any forward-looking statement speaks only as of the date of this press release. Factors or events that could cause Acelity’s actual results to differ may emerge from time to time, and it is not possible to predict all of them. Acelity may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. Acelity’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions Acelity may make. Acelity undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

For more information, contact: 


Maggie Fairchild

Corporate Communications

Phone: +1-210-330-2667



Jathan Tucker,

Investor Relations

Phone: +1-210-255-6817